Oxcarbazepine extended-release - Supernus Pharmaceuticals

Drug Profile

Oxcarbazepine extended-release - Supernus Pharmaceuticals

Alternative Names: Epliga; OXC-XR; Oxcarbazepine QD; Oxtellar XR; SPN-804

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator Supernus Pharmaceuticals
  • Class Antiepileptic drugs; Dibenzazepines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Partial epilepsies

Most Recent Events

  • 12 Dec 2016 US Court of Appeals for the Federal Circuit affirmed the New Jersey District Court’s decision that Actavis had infringed two oxcarbazepine extended-release Orange Book patents
  • 15 Mar 2016 Biomarkers information updated
  • 26 Feb 2016 Aequus Pharmaceuticals plans to launch Oxcarbazepine extended release in Canada in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top